TIETOJA TÄSTÄ JAKSOSTA
Prof van Dongen speaks with ecancertv at IBCD 2016 about gaining deeper insight into drug action and suitability with radiolabelling.
He describes how the journey of radiolabelled ligands may steer drug development, aiming for biomarkers and accumulating in tumours with localised tissue damage and low toxicity.
Prof van Dongen describes himself as a tyrosine kinase inhibitor skeptic, calling for greater clarity in patient subtypes.
He describes how the journey of radiolabelled ligands may steer drug development, aiming for biomarkers and accumulating in tumours with localised tissue damage and low toxicity.
Prof van Dongen describes himself as a tyrosine kinase inhibitor skeptic, calling for greater clarity in patient subtypes.
Englanti
Yhdysvallat
TRANSKRIPTIO 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
HAE EDELLISIÄ EPISODEJA
Hae kanavan IBCD 2016 vanhoja jaksoja.
MUITA jaksoja TÄSSÄ PODCASTISSA
Dr Beer speaks with ecancertv at IBCD 2016 about making use of genomic data in a clinically actionable setting.
He opens with comments on the work of Dr Moritz Gerstung and considers the issues of storage, access and regulation in genomic libraries.
Dr Beer describes how unregulated access and of…
Dr Malik speaks with ecancertv at IBCD 2016 to discuss the work of the National Cancer Institute in recruiting patients to clinical trials when subtyping limits disease-wide enrollment.
She describes how 'exceptional responders' can be referred to the NCI for genotyping, and schemes to match patie…
Dr Gerstung speaks with ecancertv at IBCD 2016 about genetic analysis of AML patients that has contributed to a predictive model for treatment risk and outcomes.
He describes how modelling can be improved with wider data gathering, across populations and tumour types, though this faces the risk of…
Dr Golfinopoulos meets with ecancertv at IBCD 2016 to discuss SPECTA: a screening platform that sought to encourage patients to participate in clinical trials.
He describes how regulatory involvement in trial design and drug design could be streamlined, and the issue of reimbursement for personali…
Dr Schneider speaks with ecancertv at IBCD 2016 about the regulatory checkpoints to be passed in the development of assays.
He highlights the difference in reproducibility and robustness of research and clinical assays, the clinical utility of validated biomarkers, and how beginning assay developm…
Vastuuvapautusilmoitus: Tälle sivulle upotettu podcast ja kuvitus ovat peräisin ecancer.org:ltä, joka on sen omistajan omaisuutta, eikä se ole sidoksissa Listen Notes, Inc:n tukemaan.
MUOKKAA
Kiitos, kun autoit pitämään podcast-tietokantaa ajan tasalla.
